Clinical Trial Update: Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and tolerability of QR-421a in retinitis pigmentosa due to USH2A exon 13 mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type

Drugs mentioned

• QR-421a

Snippet

Sponsor: ProQR Therapeutics | Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1, Phase 2 | Status: COMPLETED